|Day Low/High||0.94 / 0.98|
|52 Wk Low/High||0.86 / 1.92|
Study to help guide Cellceutix in continued development of Brilacidin, including planned foam and oral formulations for hard-to-treat chronic conditions like Ulcerative Colitis and Crohn's Disease
TheStreet's Adam Feuerstein answers readers' questions about biotech stocks.
CEOs of troubled companies tend to launch public tirades against the 'evil' shorts. The rants are often a smokescreen meant to divert investors' attention from problems.
Management to provide Clinical, Regulatory and Financial Updates
Shares of the urology company surge in postmarket trading Thursday.
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...
Goldberg Law PC ( http://www.Goldberglawpc.